King Minos II hall
King Minos III hall
Poster session
N.1A. e-Poster
Breakthrough in Nephrology
N.2A. Changing the status quo in CKD
1. SGLT2 inhibitors: what's new?
2. The place of GLP-1 agonists in the treatment of CKD
3. The place of MRAs in clinical practice
Cardiovascular morbidity
N.3A. Hypertension
1. Management of hypertension in patients with CKD
2. Resistant hypertension
3. Use of diuretics in CKD: benefits and risks
N.4A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new?
2. Challenges in the management of heart failure in patients with CKD
3. Update in the management of hyperkalaemia
Haemodialysis
N.5A. Haemodialysis
1. Uremic pruritus: systematic review, evaluation and management
2. HIF inhibitors: their place in clinical practice
3. Management of bone mineral disease: what is the target and how to achieve it
Hands-on training
N.1Β. US-guided fistula needling
Nursing & dietetics
N.2B. Renal nursing
1. Protocols in haemodialysis
2. Dry weight assessment
3. Intradialytic BP disorders: assesment & management
4. IDPN: whom for, when, and how?
Ν.3Β. Renal dietetics
1. Oral supplements in patients with CKD
2. IDPN: when, whom to, and how?
3. Diet in the patient with diabetes and CKD
_edited_edited_edited.jpg){kind=small}
Hands-on training
N.4B. Course on BLS with the use of external defibrillator
Lunch break
Generel assembly & elections
Clinical Nephrology
N.6A. IgA nephropathy
1. New and emerging therapies in IgA nephropathy
2. How should I manage the patient with IgA nephropathy
Hereditary nephropathies
N.7A. Polycystic kidney disease
1. Safety and effectiveness of Tolvaptan
2. New KDIGO Guidelines
3. Genetic tests: what should I know?
N.8A. Other hereditary nephropathies
1. Fabry Disease: what should I know?
2. Hereditary tubulointerstitial nephropathies
Close
Close
